Get notified when SONM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company faces imminent Nasdaq delisting unless it successfully appeals by May 29, 2026, with trading suspension starting June 2.
DNA X faces Nasdaq delisting by June 2 as it raises $3M via convertible note secured by subsidiary
Filed May 27, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq issued delisting notice on May 22 after company reported $983K stockholders' deficit in Q1 2026, failing minimum equity requirement. Trading suspended June 2 unless company appeals by May 29.
Item 3.01 verify on EDGAR → -
high
Company issued $3.05M convertible note to DNA Holdings Venture ($1.8M cash plus $1.25M prior note surrender), maturing Dec 2026 at 10% interest, convertible at $6/share pending stockholder approval.
Item 1.01 verify on EDGAR → -
high
Note secured by first-priority lien on DNA X LLC membership interests (company's wholly owned subsidiary), putting core operating assets at risk if company defaults on repayment.
Item 1.01 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade SONM commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 27, 2026 · How we verify